Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 11/20 | 0.65 |
| ▸ | KDM1A | O60341 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6604763 | 1.00 | TACR1 (0.65) | TACR1KDM1AMAOAMAOBHCRTR2 | |
| SCHEMBL7594455 | 0.87 | TACR1 (0.50) | TACR1HCRTR2 | |
| SCHEMBL7594451 | 0.87 | TACR1 (0.50) | TACR1HCRTR2 | |
| SCHEMBL7867202 | 0.86 | TACR1 (0.60) | TACR1 | |
| SCHEMBL7591379 | 0.86 | TACR1 (0.49) | TACR1HCRTR2 | |
| SCHEMBL7137909 | 0.86 | TACR1 (0.51) | TACR1 | |
| SCHEMBL7135463 | 0.86 | TACR1 (0.51) | TACR1 | |
| SCHEMBL7133654 | 0.86 | TACR1 (0.60) | TACR1 | |
| SCHEMBL8708427 | 0.86 | TACR1 (0.51) | TACR1 | |
| SCHEMBL7864432 | 0.86 | TACR1 (0.58) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105124-A1 | Substituted benzolactam compounds | SOBOLOV-JAYNES SUSAN BETH (US) | 2003-06-05 | — | — | US | disclosed |
| EP-0780375-B1 | 3-((5-substituted benzyl)amino)-2-phenylpiperidines as substance p antagonists | PFIZER (US) | 2002-09-11 | — | — | EP | disclosed |
| US-20020052503-A1 | Substituted benzolactam compounds as substance p antagonists | WAKABAYASHI HIROAKI (JP) | 2002-05-02 | — | — | US | disclosed |
| US-6288225-B1 | Substituted benzolactam compounds as substance P antagonists | PFIZER INC | 2001-09-11 | — | — | US | disclosed |
| US-6180647-B1 | GASTROINTESTINAL DISORDERS; NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2001-01-30 | — | — | US | disclosed |
| US-6143767-A | SUBSTANCE P ANTAGONIST | PFIZER INC (US) | 2000-11-07 | — | — | US | disclosed |
| EP-0824100-B1 | Piperidinylamino tricyclic compouds as substance P antagonists | PFIZER (US) | 2000-09-20 | — | — | EP | disclosed |
| US-5972930-A | TREATING GASTROINTESTINAL DISORDER, A CENTRAL NERVOUS SYSTEM DISORDER, AN INFLAMMATORY DISEASE, EMESIS, URINARY INCONTINENCE, PAIN, MIGRAINE, SUNBURN, ANGIOGENESIS, DISEASES CAUSED BY HELICOBACTER PYLORI | PFIZER, INC. (US) | 1999-10-26 | — | — | US | disclosed |
| US-5789423-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS; GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. (US) | 1998-08-04 | — | — | US | disclosed |
| EP-0824100-A1 | Piperidinylamino tricyclic compouds as substance P antagonists | PFIZER INC. (US) | 1998-02-18 | — | — | EP | disclosed |
| EP-0780375-A1 | 3-((5-substituted benzyl)amino)-2-phenylpiperidines as substance p antagonists | PFIZER INC. (US) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105124-A1 | Substituted benzolactam compounds | NPY1R, HAX1, CBR1 | TACR1 687/4885KDM1A 56/4885MAOA 1034/4885 |
| US-20020052503-A1 | Substituted benzolactam compounds as substance p antagonists | NPY1R, OPRM1, OPRL1 | TACR1 4/4885KDM1A 789/4885MAOA 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.